| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
785.40(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,006,201 |
| 52
Week Range: |
$12.64 - $30.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
48,477 |
278,477 |
| Total Buy Value |
$0 |
$0 |
$831,428 |
$6,164,449 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Friedmann Nadav |
Chief Operating Officer |
• • – |
2010-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,826 |
282,665 |
|
- |
|
| Barbier Remi |
CEO, Chairman of the Board |
• • • |
2010-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
33,786 |
5,963,373 |
|
- |
|
| Roddy Peter S |
Chief Financial Officer |
• – – |
2010-11-01 |
4 |
A |
$3.77 |
$6,262 |
D/D |
1,661 |
44,057 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2010-11-01 |
4 |
A |
$3.77 |
$7,118 |
D/D |
1,888 |
277,839 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-10-04 |
4 |
AS |
$6.13 |
$91,950 |
D/D |
(15,000) |
5,929,587 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-10-01 |
4 |
AS |
$6.23 |
$218,050 |
D/D |
(35,000) |
5,944,587 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-09-07 |
4 |
AS |
$5.60 |
$91,078 |
D/D |
(16,264) |
5,979,587 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-09-03 |
4 |
AS |
$5.80 |
$71,531 |
D/D |
(12,333) |
5,995,851 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-09-02 |
4 |
AS |
$5.87 |
$65,139 |
D/D |
(11,097) |
6,008,184 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-09-01 |
4 |
AS |
$5.75 |
$59,260 |
D/D |
(10,306) |
6,019,281 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-08-09 |
4 |
AS |
$5.81 |
$37,586 |
D/D |
(6,468) |
6,029,587 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-08-06 |
4 |
AS |
$5.53 |
$52,541 |
D/D |
(9,496) |
6,036,055 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-08-05 |
4 |
AS |
$5.60 |
$19,624 |
D/D |
(3,505) |
6,045,551 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-08-04 |
4 |
AS |
$5.64 |
$37,129 |
D/D |
(6,582) |
6,049,056 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-08-03 |
4 |
AS |
$5.75 |
$37,108 |
D/D |
(6,457) |
6,055,638 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-08-02 |
4 |
AS |
$5.74 |
$53,709 |
D/D |
(9,352) |
6,062,095 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-07-16 |
4 |
AS |
$5.54 |
$8,310 |
D/D |
(1,500) |
48,157 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-07-16 |
4 |
OE |
$4.40 |
$6,600 |
D/D |
1,500 |
49,687 |
|
- |
|
| Barbier Remi |
CEO and Chairman of the Board |
• • • |
2010-07-07 |
4 |
AS |
$5.37 |
$37,964 |
D/D |
(7,071) |
6,071,447 |
|
- |
|
| Barbier Remi |
CEO and Chairman of the Board |
• • • |
2010-07-06 |
4 |
AS |
$5.34 |
$107,658 |
D/D |
(20,172) |
6,078,518 |
|
- |
|
| Barbier Remi |
CEO and Chairman of the Board |
• • • |
2010-07-02 |
4 |
AS |
$5.42 |
$59,977 |
D/D |
(11,065) |
6,098,690 |
|
- |
|
| Barbier Remi |
CEO and Chairman of the Board |
• • • |
2010-07-01 |
4 |
AS |
$5.42 |
$63,378 |
D/D |
(11,692) |
6,109,755 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-06-16 |
4 |
AS |
$5.45 |
$8,175 |
D/D |
(1,500) |
48,187 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-06-16 |
4 |
OE |
$4.40 |
$6,600 |
D/D |
1,500 |
49,687 |
|
- |
|
| Barbier Remi |
CEO and Chairman of Board |
• • • |
2010-06-03 |
4 |
AS |
$5.53 |
$45,564 |
D/D |
(8,238) |
6,121,447 |
|
- |
|
504 Records found
|
|
Page 7 of 21 |
|
|
0.31 (1.55%) 
